We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Innovative Technology Identifies Broad Range of Pathogens

By LabMedica International staff writers
Posted on 23 Sep 2014
Print article
Abbott\'s diagnostic platform system IRIDICA for the identification of pathogens
The diagnostic platform system IRIDICA for the identification of pathogens (Photo courtesy of ABBOTT Corporate)
A platform has been developed with the goal to deliver a broad range of tests that can identify hundreds of bacteria, fungi, and viruses directly from a patient specimen within eight hours.

The pioneering testing technology could reduce hospital stays by up to eight days and lower annual health care costs for people with serious infections by approximately USD 2.2 million.

The cost reductions were based on a health economic model from the RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study. An independent, expert panel of physicians reviewed the RADICAL study results from samples obtained from 420 critically ill patients with suspected severe infections from the United Kingdom, France, Belgium, Poland, Switzerland, and Germany.

The RADICAL study indicated that polymerase chain reaction/Electrospray Ionization Mass Spectrometry or PCR/ESI-MS (Abbott, Abbot Park, IL, USA) has the ability to detect the source of the infection such as bacteria, fungi, or viruses, within hours, even when blood cultures, the current standard of care, are negative. This information could help doctors diagnose and initiate appropriate treatments more quickly.

The platform known as IRIDICA currently differentiates between 600 bacterial families, as well as 200 families of fungi and 13 families of viruses. The PCR/ESI-MS technology may offer the potential for earlier discontinuation of broad-spectrum antibiotics. After retrospectively comparing Abbott's technology versus culture, the physicians reported they would have prescribed a different course of treatment in 57% of the cases evaluated based on the Abbott technology results.

Jean-Louis Vincent, MD, PhD, professor of Intensive Care at the Universite Libre de Bruxelles (Brussels, Belgium) said, “More than 50% of blood culture tests come back negative, even when infections are believed to exist. The results of the RADICAL study and the economic analysis suggest the Abbott technology will provide actionable information much earlier, allow physicians to improve patient outcomes and may ultimately lower overall health care costs related to these serious infections.” The IRIDICA platform is expected to be available as a Conformité Européenne (CE) marked in vitro diagnostic device in European countries within the coming months. The study was presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy held September 5-9, 2014, in Washington DC (USA).

Related Links:

Abbott
Universite Libre de Bruxelles


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Reagent Reservoirs
Reagent Reservoirs
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.